David W. Nassif - 08 Feb 2022 Form 4 Insider Report for Sio Gene Therapies Inc.

Reporting relationship: Interim CEO, CFO, Director
Issuer ticker: N/A
Reported as of: 08 Feb 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 10 Feb 2022, 16:05:27 UTC
Prior SEC filing: 09 Dec 2021
Next SEC filing: 18 Mar 2026
Source filing: View source filing
Reporting owner signature: /s/ David Nassif

Key filing fact

David W. Nassif filed Form 4 for Sio Gene Therapies Inc. on 10 Feb 2022.

Key facts

This page summarizes David W. Nassif's Form 4 filing for Sio Gene Therapies Inc..
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 10 Feb 2022, 16:05.

Change

Previous filing in this sequence was filed on 09 Dec 2021.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

SIOX transaction Derivative

Restricted Stock Units

Award

Transaction value: $0
Shares: +546,500
Change %
Price: $0.000000
Shares after: 546,500
Date: 08 Feb 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 546,500
Exercise price
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Each restricted stock unit represents the right to receive one share of the Issuer's common stock.

Footnote F2

One-third of the restricted stock units shall vest on February 8, 2023, February 8, 2024 and February 8, 2025, subject to the Reporting Person providing continuous service to the Issuer through each such date.